Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Plethora Solutions PLC

4 Mar 2016 11:59

RNS Number : 0776R
Peel Hunt LLP
04 March 2016
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Plethora Solutions Holdings PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

Regent Pacific Group Limited

(d) Date dealing undertaken:

3 March 2016

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Buy

5,253,086

3.00 GBx

2.55 GBx

Ordinary Shares

Sale

3,824,407

3.25 GBx

3.00 GBx

 

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:/

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

4 March 2016

Contact name:

Spencer Harding

Telephone number:

0203 597 8658

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERKZLBBQXFXBBX
Date   Source Headline
26th Feb 20077:03 amRNSClinical Update - PSD510
22nd Feb 20077:02 amRNSClinical Update - PSD502
8th Feb 20077:01 amRNSClinical Update
21st Dec 20062:30 pmRNSTotal Voting Rights
5th Dec 20067:03 amRNSProduct Update - ErecAid
27th Nov 20067:01 amRNSProduct Update PSD401
9th Oct 20067:00 amRNSFDA grants label extension
4th Oct 200610:02 amRNSOptions Award
25th Sep 20067:04 amRNSFDA Approval
25th Sep 20067:03 amRNSInterim Results
13th Sep 200611:44 amRNSNotice of Results
22nd Aug 20067:01 amRNSSenior Management Appointment
22nd Aug 20067:01 amRNSClinical Update
10th Aug 20067:00 amRNSSenior Appointment
8th Aug 20067:01 amRNSClinical Update
22nd Jun 20067:02 amRNSIn-Licence and Placing
1st Jun 20067:01 amRNSRe Agreement
27th Apr 20064:11 pmRNSAnnual General Meeting
6th Apr 20064:47 pmRNSShare Options Award
4th Apr 20067:01 amRNSPrelim Results 31 Dec 05
16th Mar 20069:01 amRNSNotice of Results
2nd Mar 20067:00 amRNSFDA Accept Phase II ( PSD597)
21st Feb 20067:01 amRNSLicensing Agreement
13th Feb 20061:27 pmRNSHolding(s) in Company
10th Feb 200611:34 amRNSResult of EGM
6th Feb 200611:25 amRNSResult of EGM
3rd Feb 20065:30 pmRNSHolding(s) in Company
31st Jan 20065:02 pmRNSHolding(s) in Company
13th Jan 20067:30 amRNSProposed Acq and Placing
16th Dec 20057:00 amRNSPSD502 Final Clinical Data
7th Dec 200511:23 amRNSHolding(s) in Company
1st Dec 20057:00 amRNSPSD502 Clinical Trial Data
30th Nov 20052:22 pmRNSHolding(s) in Company
20th Oct 20057:00 amRNSPhase II Clinical Study
26th Sep 20057:03 amRNSInterim Results
26th Sep 20057:00 amRNSProduct Acquisition
12th Sep 20057:00 amRNSPhase II Clinical Trials
31st Aug 20059:38 amRNSNotice of Results
26th Jul 20057:00 amRNSClinical Update
13th Jul 20057:00 amRNSCollaborative Agreement
30th Jun 20058:30 amRNSShare Options Award
22nd Jun 20057:00 amRNSClinical Update
19th May 20057:00 amRNSDirector Dealings
28th Apr 20054:05 pmRNSHolding(s) in Company
18th Apr 20057:00 amRNSRoche Announcement
24th Mar 20058:00 amRNSFirst Day Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.